WHI estrogen-only arm is canceled

Maturitas

Volumn 48, Issue 1, 2004, Pages 3-4

  Speroff, Leon ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN; ESTROGEN; GESTAGEN; PLACEBO;

BREAST CANCER; CANCER RISK; CLINICAL TRIAL; COGNITIVE DEFECT; CORONARY RISK; DEMENTIA; DRUG EFFECT; ESTROGEN THERAPY; FOLLOW UP; HEALTH CARE ORGANIZATION; HEART INFARCTION; HIP FRACTURE; HORMONE SUBSTITUTION; HUMAN; HYSTERECTOMY; ISCHEMIC HEART DISEASE; MENOPAUSAL SYNDROME; MENOPAUSE; NOTE; POSTMENOPAUSE; PRIMARY PREVENTION; RISK BENEFIT ANALYSIS; RISK REDUCTION; SIDE EFFECT; STATISTICAL SIGNIFICANCE; STROKE;

ESTROGEN REPLACEMENT THERAPY; FEMALE; HEALTHY PEOPLE PROGRAMS; HUMANS; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN; UNITED STATES; WOMEN'S HEALTH;

EID: 3042637227     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2004.03.002     Document Type: Note

References (3)

1. National Heart, Lung, and blood Institute. www.nhlbi.nig.gov/whi; 2004.
2. Manson J.E., Hsia J., Johnson K.C., et al. Estrogen plus progestin and the risk of coronary heart disease. N. Eng. J. Med. 349:2003;523-534
3. Writing group for the women's health initiative investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33.